Allogene Therapeutics (ALLO) Capital Expenditures (2018 - 2026)

Allogene Therapeutics has reported Capital Expenditures for 9 years, with the latest figure at $9000.0 in Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 145.84% YoY) and the FY2025 annual result came in at $1.3 million, up 130.15% from the prior year.
• Capital Expenditures slipped to $9000.0 in Q1 2026 per ALLO's latest filing, from $102000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.0 million in Q4 2022 and troughed at -$4.7 million in Q4 2024.
• A 5-year average of $229125.0 and a median of $422500.0 in 2022 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 673.91% in 2022, then sank 4030.0% in 2024.
• Over 5 years, Capital Expenditures stood at $2.0 million in 2022, then plunged by 93.94% to $120000.0 in 2023, then tumbled by 4030.0% to -$4.7 million in 2024, then jumped by 102.16% to $102000.0 in 2025, then sank by 91.18% to $9000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $9000.0, $102000.0, and $973000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.